We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+58.37%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$238M
AUM Growth
+$43M
Cap. Flow
-$40.1M
Cap. Flow %
-16.84%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$36.1M
2
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
+$4.03M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$175M 73.33%
3,146,630
-800,000
-20% -$36.1M
SPRY icon
2
ARS Pharmaceuticals
SPRY
$591M
$22M 9.23%
4,012,903
– –
DSGN icon
3
Design Therapeutics
DSGN
$915M
$17.3M 7.26%
6,526,476
– –
MLYS icon
4
Mineralys Therapeutics
MLYS
$2.41B
$15.4M 6.48%
1,794,600
– –
NKTX icon
5
Nkarta
NKTX
$167M
$8.8M 3.7%
1,333,333
– –
EFTR
6
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
– –
-272,885
Closed -$4.03M

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, SR One Capital Management held 6 positions worth $238M, up 22% from $195M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SR One Capital Management withdrew a net $40.1M in Q4 2023, closing 1 position and reducing 1 holding. Its most notable exit was eFFECTOR Therapeutics, Inc. Common Stock, an estimated $4.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's biggest Q4 2023 reduction was Arcellx, cutting an estimated $36.1M.
  • SR One Capital Management fully exited eFFECTOR Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $4.03M.
  • SR One Capital Management's ten largest holdings make up 100% of its $238M portfolio in Q4 2023.
  • SR One Capital Management opened 0 new positions and closed 1 in Q4 2023.
  • SR One Capital Management's portfolio value rose 22% quarter-over-quarter to $238M.

Based on SR One Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.